As already informed to the exchange, Bal Pharma has informed that the Board of Directors of the Company met on 14/11/2019 and approved the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended 30/09/2019, which was subjected to limited review by the statutory auditors of the Company. Certified copy of the unaudited financial results along with the copy of the limited review report issued by the statutory auditors is enclosed with this letter for submission to the Exchange; and appointed G.Rengarajan as Chief Financial Officer (CFO) of the Company in place of Chaitanya A.N.V.K, who has resigned citing personal reasons. G. Rengarajan is a Cost and Management Accountant (CMA) from ICWAI with over 20 years of experience in the fields of finance and accounts from various prominent Companies. The Board meeting commenced at 5 PM and concluded at 9 PM on 14.11.2019.
The above information is a part of company’s filings submitted to BSE.
